Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.

As the incidence of azole resistance in Aspergillus fumigatus is rising and the diagnosis of invasive aspergillosis (IA) in immunocompromised patients is rarely based on positive culture yield, we screened our Aspergillus DNA sample collection for the occurrence of azole resistance mediating cyp51 A...

Full description

Bibliographic Details
Main Authors: Birgit Spiess, Patricia Postina, Mark Reinwald, Oliver A Cornely, Axel Hamprecht, Martin Hoenigl, Cornelia Lass-Flörl, Peter-Michael Rath, Jörg Steinmann, Thomas Miethke, Melchior Lauten, Silke Will, Natalia Merker, Wolf-Karsten Hofmann, Dieter Buchheidt
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25072733/?tool=EBI
id doaj-e99678bdea7548a8b743e8a48bca6a76
record_format Article
spelling doaj-e99678bdea7548a8b743e8a48bca6a762021-03-03T20:13:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0197e10311310.1371/journal.pone.0103113Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.Birgit SpiessPatricia PostinaMark ReinwaldOliver A CornelyAxel HamprechtMartin HoeniglCornelia Lass-FlörlPeter-Michael RathJörg SteinmannThomas MiethkeMelchior LautenSilke WillNatalia MerkerWolf-Karsten HofmannDieter BuchheidtAs the incidence of azole resistance in Aspergillus fumigatus is rising and the diagnosis of invasive aspergillosis (IA) in immunocompromised patients is rarely based on positive culture yield, we screened our Aspergillus DNA sample collection for the occurrence of azole resistance mediating cyp51 A key mutations. Using two established, a modified and a novel polymerase chain reaction (PCR) assays followed by DNA sequence analysis to detect the most frequent mutations in the A. fumigatus cyp51 A gene conferring azole resistance (TR34 (tandem repeat), L98H and M220 alterations). We analyzed two itraconazole and voriconazole and two multi-azole resistant clinical isolates and screened 181 DNA aliquots derived from clinical samples (blood, bronchoalveolar lavage (BAL), biopsies, cerebrospinal fluid (CSF)) of 155 immunocompromised patients of our Aspergillus DNA sample collection, previously tested positive for Aspergillus DNA and collected between 1995 and 2013. Using a novel PCR assay for the detection of the cyp51 A 46 bp tandem repeat (TR46) directly from clinical samples, we found the alteration in a TR46/Y121F/T289A positive clinical isolate. Fifty stored DNA aliquots from clinical samples were TR46 negative. DNA sequence analysis revealed a single L98H mutation in 2010, two times the L98H alteration combined with TR34 in 2011 and 2012 and a so far unknown N90K mutation in 1998. In addition, four clinical isolates were tested positive for the TR34/L98H combination in the year 2012. We consider our assay of epidemiological relevance to detect A. fumigatus azole resistance in culture-negative clinical samples of immunocompromised patients; a prospective study is ongoing.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25072733/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Birgit Spiess
Patricia Postina
Mark Reinwald
Oliver A Cornely
Axel Hamprecht
Martin Hoenigl
Cornelia Lass-Flörl
Peter-Michael Rath
Jörg Steinmann
Thomas Miethke
Melchior Lauten
Silke Will
Natalia Merker
Wolf-Karsten Hofmann
Dieter Buchheidt
spellingShingle Birgit Spiess
Patricia Postina
Mark Reinwald
Oliver A Cornely
Axel Hamprecht
Martin Hoenigl
Cornelia Lass-Flörl
Peter-Michael Rath
Jörg Steinmann
Thomas Miethke
Melchior Lauten
Silke Will
Natalia Merker
Wolf-Karsten Hofmann
Dieter Buchheidt
Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
PLoS ONE
author_facet Birgit Spiess
Patricia Postina
Mark Reinwald
Oliver A Cornely
Axel Hamprecht
Martin Hoenigl
Cornelia Lass-Flörl
Peter-Michael Rath
Jörg Steinmann
Thomas Miethke
Melchior Lauten
Silke Will
Natalia Merker
Wolf-Karsten Hofmann
Dieter Buchheidt
author_sort Birgit Spiess
title Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
title_short Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
title_full Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
title_fullStr Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
title_full_unstemmed Incidence of Cyp51 A key mutations in Aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
title_sort incidence of cyp51 a key mutations in aspergillus fumigatus-a study on primary clinical samples of immunocompromised patients in the period of 1995-2013.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description As the incidence of azole resistance in Aspergillus fumigatus is rising and the diagnosis of invasive aspergillosis (IA) in immunocompromised patients is rarely based on positive culture yield, we screened our Aspergillus DNA sample collection for the occurrence of azole resistance mediating cyp51 A key mutations. Using two established, a modified and a novel polymerase chain reaction (PCR) assays followed by DNA sequence analysis to detect the most frequent mutations in the A. fumigatus cyp51 A gene conferring azole resistance (TR34 (tandem repeat), L98H and M220 alterations). We analyzed two itraconazole and voriconazole and two multi-azole resistant clinical isolates and screened 181 DNA aliquots derived from clinical samples (blood, bronchoalveolar lavage (BAL), biopsies, cerebrospinal fluid (CSF)) of 155 immunocompromised patients of our Aspergillus DNA sample collection, previously tested positive for Aspergillus DNA and collected between 1995 and 2013. Using a novel PCR assay for the detection of the cyp51 A 46 bp tandem repeat (TR46) directly from clinical samples, we found the alteration in a TR46/Y121F/T289A positive clinical isolate. Fifty stored DNA aliquots from clinical samples were TR46 negative. DNA sequence analysis revealed a single L98H mutation in 2010, two times the L98H alteration combined with TR34 in 2011 and 2012 and a so far unknown N90K mutation in 1998. In addition, four clinical isolates were tested positive for the TR34/L98H combination in the year 2012. We consider our assay of epidemiological relevance to detect A. fumigatus azole resistance in culture-negative clinical samples of immunocompromised patients; a prospective study is ongoing.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25072733/?tool=EBI
work_keys_str_mv AT birgitspiess incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT patriciapostina incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT markreinwald incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT oliveracornely incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT axelhamprecht incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT martinhoenigl incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT cornelialassflorl incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT petermichaelrath incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT jorgsteinmann incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT thomasmiethke incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT melchiorlauten incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT silkewill incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT nataliamerker incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT wolfkarstenhofmann incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
AT dieterbuchheidt incidenceofcyp51akeymutationsinaspergillusfumigatusastudyonprimaryclinicalsamplesofimmunocompromisedpatientsintheperiodof19952013
_version_ 1714823534419640320